VIRUS STRAINS
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention relates to clinical herpes simplex virus (HSV) isolates with improved oncolytic capabilities as compared to reference laboratory HSV strains. The present invention also relates to methods of producing HSV strains of the invention and to pharmaceutical compositions comprising a HSV strain of the invention.
-
Citations
77 Claims
-
1-61. -61. (canceled)
-
62. A modified, oncolytic herpes simplex virus (HSV) strain comprising:
- a modified, oncolytic herpes simplex virus (HSV) strain wherein said HSV strain is a clinical isolate from a recurrent cold sore and has a greater ability than a reference laboratory HSV strain modified in the same manner as the clinical isolate to replicate in or kill tumor cells, and wherein said reference laboratory HSV strain is selected from the group consisting of HSV1 strain 17+, HSV1 strain F and HSV1 strain KOS.
- View Dependent Claims (63, 64, 65, 66, 67, 68, 69, 70, 71, 72)
-
73. A method of determining the suitability of a herpes simplex virus (HSV) strain for use in the production of a modified, oncolytic HSV strain, wherein said HSV strain is a clinical isolate, said method comprising:
-
(i) providing an HSV virus strain to be evaluated; (ii) assessing the ability of said HSV to replicate in or kill tumor cells; and
,selecting for modification HSV strains which have a greater ability than one or more reference strains selected from the group consisting of HSV1 strain 17+, HSV1 strain F and HSV1 strain KOS, to replicate in or kill tumor cells. - View Dependent Claims (74, 75, 76, 77)
-
Specification